dihydrocodeine

Small moleculeapproved

Approved

Jul 7, 1958

Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain. It can also be used to treat chronic pain, breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. — NCATS

Clinical trial activity

2 trials · 4 clinical orgs · 11 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2007 (NCT00547885)

Timeline

1910s

Jul 1, 1911
Evidence of US Marketing

1950s

Jul 7, 1958
Sun Pharmaceuticals — Earliest FDA Approval
Jul 7, 1958
Sun Pharmaceuticals — NDA Secondary Org
Jul 7, 1958
Sun Pharmaceuticals — NDA Organization

1980s

Mar 4, 1986
Pharmaceutical Research Associates, Inc. (PRA) — Marketing Organization
May 14, 1986
Leitner Pharms — Marketing Organization

1990s

Aug 26, 1997
Mikart — Marketing Organization

2000s

Sep 22, 2006
West-Ward Pharmaceutical — Marketing Organization
Apr 3, 2007
Boca Pharmacal — Marketing Organization
Apr 3, 2007
Wraser Pharmaceuticals — Marketing Organization

2010s

Nov 26, 2014
Xspire Pharma — Marketing Organization
Nov 26, 2014
KEY THERAP — Marketing Organization
Sep 30, 2016
Larken Labs Inc — Marketing Organization
Sep 30, 2016
PHARMOBEDIENT — Marketing Organization

Indications

Approved for

Pain

Studied for

Pain · Phase 4

Mechanism of action

Mu opioid receptorAGONIST
OPRM agonist
- Mu-type opioid receptor (OPRM) ↗

Combination products

dhc plus
with acetaminophen, caffeine
Also known as synalgos-dc-a, trezix
synalgos-dc
with caffeine, acetylsalicylic acid

Approval history

approvedJul 7, 1958
approvedJul 1, 1911

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341

Mol. weight: 301.39 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Discontinued

Oral

Yes

Parenteral

Topical

Sources

Also known as

codhydrine
cohydrin
contugesic
dehacodin
df 118
df-118
df-118
dhc
dhc
dhc continus
dhc mundipharma
dicodin
dihydric
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine
dihydrocodeine, (5alpha,6alpha,14alpha)-isomer
dihydrocodeine, (5alpha,6beta,14alpha)-isomer
dihydrocodeine, (5alpha,6beta)-isomer
dihydrocodeine acetate, (5alpha,6alpha)-isomer
dihydrocodeine bitartrate
dihydrocodeine bitartrate
dihydrocodeine bitartrate
dihydrocodeine bitartrate
dihydrocodeine hydrochloride, (5alpha,6alpha)-isomer
dihydrocodeine phosphate
dihydrocodeine phosphate
dihydrocodeine phosphate
dihydrocodeine phosphate (1:1), (5alpha,6alpha)-isomer
dihydrocodeine tartrate (1:1), (5alpha,6alpha)-(r-(r*,r*))-isomer
dihydrocodeine tartrate (1:1), (5alpha,6beta)-(r-(r*,r*))-isomer
dihydrocodeine, thiocyanate salt (5alpha,6alpha)-isomer
dihydroneopine
dihydroneopine
dihydroneopine
drocode
drocode
hydrocodeine
hydrocodin
paracodin
paracodina
paramol 118
parzone bitartrate
remedacen
remedacen
rikodeine
tiamon
tosidrin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03902340	N/A	Dec 19, 2018	Eurofins, Hôpital Roger Salengro, Sublimed
NCT00547885	Phase 4	Oct 1, 2007	Norwegian University of Science and Technology

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Eurofins	For profit	1	0	1	2018
Hôpital Roger Salengro	Academic/Hospital	1	0	1	2018
Norwegian University of Science and Technology	Academic/Hospital	1	1	1	2007
Sublimed	For profit	1	1	1	2018

4 organizations

Page 1 / 1

Marketing (12)

Organization	Org type	Relationship	Date
Boca Pharmacal	For profit	MKTG	Apr 3, 2007
KEY THERAP	For profit	MKTG	Nov 26, 2014
Larken Labs Inc	For profit	MKTG	Sep 30, 2016
Leitner Pharms	For profit	MKTG	May 14, 1986
Mikart	For profit	MKTG	Aug 26, 1997
PHARMOBEDIENT	For profit	MKTG	Sep 30, 2016
Pharmaceutical Research Associates, Inc. (PRA)	For profit	MKTG	Mar 4, 1986
Sun Pharmaceuticals	For profit	NDA2	Jul 7, 1958
Sun Pharmaceuticals	For profit	NDA	Jul 7, 1958
West-Ward Pharmaceutical	For profit	MKTG	Sep 22, 2006
Wraser Pharmaceuticals	For profit	MKTG	Apr 3, 2007
Xspire Pharma	For profit	MKTG	Nov 26, 2014